A Phase 2 study evaluating the safety and efficacy of bamlanivimab, an experimental antibody treatment developed by Eli Lilly and Co, has shown potential for treating Covid-19 patients outside a hospital setting. The study was published in The New England Journal of Medicine on 28 October 2020.
Bamlanivimab is an IgG1 monoclonal antibody that binds to the receptor-binding domain of SARS-CoV-2 in order to block entry of the virus into human cells. The antibody was derived from convalescent plasma from a Covid-19 patient.